Table 4.
Outpatient | Inpatient | |||
---|---|---|---|---|
Lorcaserin dose (mg BID) | 0 | 10 | 0 | 10 |
Headache | 1 (1) | 3 (3) | 1 (1) | 5 (3) |
Gastrointestinal upset | 2 (2) | 1 (1) | 4 (4) | 11 (6) |
Fatigue | 1 (1) | 2 (2) | 0 (0) | 0 (0) |
Body pain | 0 (0) | 0 (0) | 1 (1) | 1 (1) |
Jittery/anxiety | 0 (0) | 1 (1) | 1 (1) | 1 (1) |
Eye-dryness/discomfort | 0 (0) | 0 (0) | 1 (1) | 4 (2) |
Trouble sleeping | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
Note: Data reflect the number of times each symptom was reported during the outpatient phase (2 days/dose) and inpatient phase (11 days/dose) as a function of lorcaserin dose; the number of participants reporting each symptom is in parentheses (max = 15).